Senestech (NASDAQ:SNES) Major Shareholder Glenbrook Capital Management Buys 15,390 Shares of Stock

Senestech, Inc. (NASDAQ:SNES) major shareholder Glenbrook Capital Management acquired 15,390 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were bought at an average cost of $1.89 per share, with a total value of $29,087.10. Following the transaction, the insider directly owned 633,700 shares of the company’s stock, valued at $1,197,693. The trade was a 2.49% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Glenbrook Capital Management also recently made the following trade(s):

• On Thursday, February 12th, Glenbrook Capital Management purchased 7,956 shares of Senestech stock. The shares were purchased at an average price of $1.72 per share, for a total transaction of $13,684.32.
• On Wednesday, February 11th, Glenbrook Capital Management purchased 8,000 shares of Senestech stock. The stock was purchased at an average cost of $1.73 per share, with a total value of $13,840.00.
• On Thursday, February 5th, Glenbrook Capital Management acquired 2,884 shares of Senestech stock. The stock was purchased at an average price of $1.77 per share, with a total value of $5,104.68.
• On Wednesday, February 4th, Glenbrook Capital Management bought 5,685 shares of Senestech stock. The stock was acquired at an average cost of $1.82 per share, for a total transaction of $10,346.70.
• On Monday, February 2nd, Glenbrook Capital Management purchased 42,739 shares of Senestech stock. The stock was bought at an average price of $1.98 per share, for a total transaction of $84,623.22.
• On Friday, January 30th, Glenbrook Capital Management purchased 5,399 shares of Senestech stock. The stock was purchased at an average price of $1.87 per share, for a total transaction of $10,096.13.

Senestech Trading Up 12.4%

Shares of SNES opened at $2.00 on Friday. Senestech, Inc. has a 52-week low of $1.30 and a 52-week high of $6.24. The company has a market cap of $10.44 million, a price-to-earnings ratio of -0.55 and a beta of 0.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.73 and a current ratio of 15.75. The stock has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $3.42.

Institutional Trading of Senestech

Several hedge funds have recently bought and sold shares of SNES. Geode Capital Management LLC acquired a new position in shares of Senestech in the second quarter valued at approximately $59,000. Corsair Capital Management L.P. bought a new stake in Senestech in the 2nd quarter valued at $255,000. Jane Street Group LLC bought a new stake in Senestech in the 2nd quarter valued at $161,000. Essex Investment Management Co. LLC acquired a new position in Senestech in the 3rd quarter worth $115,000. Finally, Sabby Management LLC bought a new position in Senestech during the 3rd quarter worth about $313,000. 5.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Senestech in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

About Senestech

SenesTech, Inc (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.

The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction.